Zobrazeno 1 - 10
of 71
pro vyhledávání: '"35"'
Autor:
Kiyoko Oshima, Stephen S. Hecht, Chieh Ti Kuo, Jo Hsin Chen, Steven G. Carmella, Noah P. Zimmerman, Gary D. Stoner, Li-Shu Wang, Jibran Siddiqui, Daniel S. Peiffer, Benjamin W. S. Ransom, Yi-Wen Huang
Publikováno v:
Cancer Prevention Research. 7:574-584
Diets containing either freeze-dried black raspberries (BRBs) or their polyphenolic anthocyanins (ACs) have been shown to inhibit the development of N-nitrosomethylbenzylamine (NMBA)–induced esophageal cancer in rats. The present study was conducte
Autor:
Ronald Linnartz, Shawnt Issakhanian, Karen A. McDonald, Richard S. Finn, S Hurvitz, Emmanuelle DiTomaso, NA O'Brien, Luo Tong, Raul Ayala, DJ Slamon, S Hirawat
Publikováno v:
Cancer Research. 73:PD1-5
Background: The selective mTORC1 inhibitor everolimus (RAD001/Affinitor®) has recently been approved, in combination with exemestane, for treatment of advanced hormone receptor positive breast cancer after demonstrating significantly improved progre
Autor:
Michael B. Foote, Daniel P. Roth, Blossom Damania, Steven I. Park, David B. Darr, Aadra P. Bhatt, Norman E. Sharpless, Carolina Lin, Dirk P. Dittmer, Trevor Parton
Publikováno v:
Molecular Cancer Research. 13:B39-B39
Background: Myc has proven extremely difficult to target therapeutically. Therefore, we hypothesized that optimal inhibition of several key targetable pathways involved in Myc signaling could overcome this long-standing problem. We identified phospho
Publikováno v:
Cancer Research. 73:2851-2851
Many solid human tumors generate an acidic and hypoxic microenvironment as a result of altered metabolic pathways and aberrant tumor vasculature. In certain tumors, the chronic exposure to acidic extracellular conditions has been reported to promote
Autor:
Mitzi Nagarkatti, Michael J. Wargovich, Deepak Poudyal, Prakash S. Nagarkatti, Alexander A. Chumanevich, Xiangli Cui, Anne B. Hofseth, Lorne J. Hofseth, Anthony Windust, Alena P. Chumanevich
Publikováno v:
Cancer Research. 72:LB-168
Patients with Ulcerative Colitis (UC) have a high risk of colon cancer. We have recently shown American Ginseng (AG) suppresses colitis, and prevents colon cancer in mice. In the present study we isolated a Hexane Fraction of AG and found this to hav
Autor:
Fatma Tat, Agatha Sheerin, David M. Goldenberg, Anju Nair, Maria Zalath, Thomas M. Cardillo, Sung-Ju Moon, Robert M. Sharkey, Serengulam V. Govindan
Publikováno v:
Cancer Research. 70:2438-2438
Antibody (MAb) conjugates of the potent topoisomerase I inhibitor, SN-38, have been previously shown by our groups to be efficacious in the targeted therapies of human cancer xenografts in nude mice. The conjugates have since been redesigned with a n
Autor:
Shu Wang, Pedro Mendez, Nigel Beard, Anders Ståhlberg, David Ruff, Göran Landberg, Saurabh Gulati, Manimozhi Manivannan, Mikael Kubista, Aik Ooi, Dalia Dhingra, Jens Björkman
Publikováno v:
Cancer Research. 80:2506-2506
The TCGA, ICGC and other research consortiums has shown that an integral, multi-omic analysis of tumors is necessary in order to understand a more complete picture of the signaling pathways involved in development, evolution, prognosis and treatment
Autor:
Dylan C. Castillejo Mijangos, Paloma Cervantes, Jinhua Wang, Zhijun Guo, Aline R. Rom'Mand, John R. Falck, Jianxun Lei, Carol A. Lange, Shaoping Wu, David Potter, Julissa Molina-Vega
Publikováno v:
Cancer Research. 80:4372-4372
Introduction: Cancer cell-intrinsic CYP monooxygenases promote tumor progression. In ER+HER2-, breast cancer cells, CYP3A4 promotes tumor growth, in part, through epoxyeicosatrienoic acid (EET) biosynthesis (1). The biguanide diabetes drug metformin
Publikováno v:
Cancer Research. 80:219-219
Fusion gene detection has long been a focus of cancer research, when combined with mutations found in gDNA, can lead to a better understanding of disease progression. One example, BCR-ABL, a marker for CML and AML stem cells, is a target for tyrosine
Autor:
Jean-Luc Van Laethem, Brenda B. Tromp, Jessica Vermeulen, Josep Tabernero, Brett Hall, Neil N. Steven, Sally S. Clive, Rajesh Bandekar, Eric Angevin, Thomas A. Puchalski, Isabelle Ray-Coquard, Christian C. Ottensmeier, Jose A. Lopez-Martin, Elena Elez, Luc Dirix, Jean-Pascal Machiels, Razelle Kurzrock, Rastilav Bahleda, Helgi van de Velde, Florence Joly, Steven Cohen, Manjula Reddy
Publikováno v:
Clinical Cancer Research. 20:2192-2204
Purpose: This phase I/II study evaluated safety, efficacy, and pharmacokinetics of escalating, multiple doses of siltuximab, a chimeric anti-interleukin (IL)-6 monoclonal antibody derived from a new Chinese hamster ovary (CHO) cell line in patients w